Tuberculosis, which is transmitted through the respiratory tract, kills more than 1.6 million people and infects more than 10 million worldwide each year.
The study ‘One to Three’ will compare the treatment completion of daily dose of Rifapentine and Isoniazid for a month (1HP) to the weekly dose of Rifapentine and Isoniazid for three months (3HP) in persons living with HIV in Pune.
The 18-month study was undertaken by researchers from B J Government Medical College (BJGMC) and Johns Hopkins University (JHU) to assess the WHO-recommended 3HP regime among People Living with HIV/AIDS (PLHIV), children living with HIV and child contacts of pulmonary TB patients.